NAD+ 100 mg

What it is

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in all living cells and central to redox metabolism. Oral precursors are sold as supplements in many markets; injectable and IV presentations sit in a different regulatory category.

Mechanism being studied

NAD+ participates in redox reactions and serves as a substrate for sirtuins and PARP enzymes, pathways studied in ageing and metabolic research.

Human evidence

Human research largely concerns oral precursors and reports biomarker changes; clinical-outcome evidence remains emerging. Evidence for injectable or IV NAD+ delivering claimed benefits is limited.

Safety considerations

Infusion-related reactions are described anecdotally. Parenteral administration should only occur in an appropriate clinical setting. Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.

Regulatory status

Regulatory classification differs between oral supplement forms and injectable presentations, and between countries. Confirm locally.

Certificate of analysis

Third-party analytical documentation for this compound is published for transparency and professional review. It confirms identity and purity of tested material only, and is not a marketing authorisation, a registration, or a recommendation for use.

Key references

• Peer-reviewed NAD+ and NAD precursor literature indexed in PubMed.
• National regulator guidance on supplements versus injectables.

References are provided as reading directions for professionals. They do not constitute endorsement of any use.